173 related articles for article (PubMed ID: 38438418)
1. Trends of Body Mass Index changes among adults on antiretroviral therapy in Northwest Ethiopia: a longitudinal data analysis.
Bantie B; Gebeyehu NA; Adella GA; Kassie GA; Mengstie MA; Abebe EC; Seid MA; Gesese MM; Tegegne KD; Anley DT; Zemene MA; Dessie AM; Feleke SF; Dejenie TA; Kebede YS; Chanie ES; Kerebeh G; Bayih WA; Moges N
Sci Rep; 2024 Mar; 14(1):5265. PubMed ID: 38438418
[TBL] [Abstract][Full Text] [Related]
2. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
5. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Chetty T; Thorne C; Coutsoudis A
PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
[TBL] [Abstract][Full Text] [Related]
6. Attrition rate and its predictors among adults receiving anti-retroviral therapy following the implementation of the "Universal Test and Treat strategy" at public health institutions in Northern Ethiopia. A retrospective follow-up study.
Bantie B; Abate MW; Nigat AB; Birlie TA; Dires T; Minuye T; Kerebeh G; Tiruneh CM; Moges N; Chanie ES; Feleke DG; Mulu AT; Demssie B; Fentie TA; Abate MD; Abate M; Ali AS; Dessie G
Heliyon; 2022 Nov; 8(11):e11527. PubMed ID: 36411907
[TBL] [Abstract][Full Text] [Related]
7. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
Ayele T; Jarso H; Mamo G
AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
[TBL] [Abstract][Full Text] [Related]
8. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
[TBL] [Abstract][Full Text] [Related]
9. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Sun L; He Y; Xu L; Zhao F; Zhou Y; Zhang L; Peng Q; Zhang H; Zhang Q; Cao T; Song Y; Wang S; Rao M; Jia X; Liu X; Zhou J; Ju B; Wang H; Liu J
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S8-S15. PubMed ID: 36094509
[TBL] [Abstract][Full Text] [Related]
10. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H
Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Li J; Chen D; Wen Z; Du Y; Huang Z; Zhong H; Wang Y; Yin S
Medicine (Baltimore); 2022 Oct; 101(42):e31100. PubMed ID: 36281149
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Johnson DC; Chasela C; Maliwichi M; Mwafongo A; Akinkuotu A; Moses A; Jamieson DJ; Kourtis AP; King CC; van der Horst C; Hosseinipour MC
PLoS One; 2012; 7(7):e41011. PubMed ID: 22848422
[TBL] [Abstract][Full Text] [Related]
13. Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy.
Dai L; Su B; Liu A; Zhang H; Wu H; Zhang T; Shao Y; Li J; Ye J; Bai S; Guo X; Sun L
BMC Infect Dis; 2020 Feb; 20(1):158. PubMed ID: 32075584
[TBL] [Abstract][Full Text] [Related]
14. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Erlandson KM; Fiorillo SP; Cardoso SW; Riviere C; Sanchez J; Hakim J; Kumarasamy N; Badal-Faesen S; Lalloo U; Kumwenda J; Campbell TB; Brown TT
AIDS Res Hum Retroviruses; 2017 Sep; 33(9):929-934. PubMed ID: 28403619
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
[TBL] [Abstract][Full Text] [Related]
16. Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study.
Hirigo AT; Yilma D; Astatkie A; Debebe Z
Ann Med; 2023; 55(2):2242250. PubMed ID: 37531412
[TBL] [Abstract][Full Text] [Related]
17. Weight change after antiretroviral therapy initiation among adults living with HIV in Northwest Ethiopia: a longitudinal data analysis.
Alebel A; Demant D; Petrucka PM; Sibbritt D
BMJ Open; 2022 Feb; 12(2):e055266. PubMed ID: 35105589
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
19. Body mass index variation over time and associated factors among HIV-positive adults on second-line ART in north-west Ethiopia: a retrospective follow-up study.
Baraki AG; Gezie LD; Zeleke EG; Awoke T; Tsegaye AT
BMJ Open; 2019 Sep; 9(9):e033393. PubMed ID: 31551394
[TBL] [Abstract][Full Text] [Related]
20. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
